The Technical Field "症状" had 47 patent application filings in the most recent period (2023-01-01 to 2023-02-28). This is a significantly decreased of -274 filings (-85.4%) over 321 they had in the same period of the previous year (2022-01-01 to 2022-02-28). This report also includes technical terms related to " 兆候 ", " 徴候 ", " 病徴 ", " 症候 ", " 症状発現 " in the search set.
The highest number of filings in 2017 with 2,954 cases, and their lowest number in 2022 with 2,040 cases.
The mean of the number of filings over the last 5 years (2018 to 2023, 13,277 cases in total) is 2,213, and the median is 2,646. The coefficient of variation (standard deviation/mean) is 0.4, and there have been big fluctuations in the number of filings from year to year.
Index | Value |
---|---|
Average | 2,213 patents |
Std Dev | 954 |
COV | 0.4 |
The number of filings has been decreasing for the last 3 years (2020 to 2023).
Year | Cases | YOY |
---|---|---|
2022 year | 2,040 cases | -25.57 % |
2021 year | 2,741 cases | +7.45 % |
2020 year | 2,551 cases | -13.47 % |
This report provides the latest patent analysis information (the IP landscape, including a patent map) on the patent search results of the JP patent database for 症状 for the period of the last 10 years (2014-01-01 to 2024-10-31). You can compare the information in this report with the trends in your competitors’ patent filings and technologies, and use it to search for important patents.
This service provides, free of charge, a patent analysis report based on the latest patent data (Japanese, U.S., European, and PCT application publications) for use in patent searches, patent analysis, and IP landscaping. The service is offered by "Patent Integration" a firm specializing in patent search/patent analysis.
This report includes basic information to help you understand the IP strategy and management of 症状, such as changes in the number of patents/patent applications they have filed, comparisons of the numbers of patents/patent applications filed by their peers and competitors, their top coapplicants (joint research partners, alliance partners), and their most important patents. It can be used in various intellectual property business operations such as IP landscaping, patent search/patent analysis, preparation of intellectual property business evaluation reports, selection of M&A candidates, and selection of alliance partners.
He is a patent attorney at a patent office. He specializes in invention counseling, patent filing, and intellectual property strategies for start-up companies and new businesses in the fields of software, information technology and artificial intelligence. He runs a patent course for beginners on Udemy, an online course provider.
After studying physics at the University of Tokyo as a doctoral student, he was engaged in intellectual property analysis and technology trend research as an in-house patent attorney at a precision equipment manufacturer and at Toyota Central R&D Labs. Inc..
The concept of the "IP landscape" (IPL) has been attracting attention recently.
An IP landscape is not limited to patent information, but also integrates and analyzes business information (e.g., non-patent information such as papers, news releases, stock information, and market information). Intellectual-property-based business management is realized through the analysis of intellectual property information applied to the formulation of management strategies and business strategies. This is a comprehensive approach that includes but not limited to planning of open and closed strategies, selecting M&A candidates, searching for alliance partners, and formulating intellectual property strategies, through the exploitation of intellectual property information.
IP landscaping usually includes patent search and patent analysis. In patent search and patent analysis, it is important to grasp the market position of each company and the overall technological trends and development trends for each technology. More specifically, it is important to understand what intellectual property your own company and other companies hold, what the strengths and weaknesses of other companies are, and how other companies are trying to exploit their intellectual property. In other words, it is important to understand both the business strategy and the intellectual property strategy of each company.
After reading this search report, you may be interested in more detailed patent searches and patent analysis. We offer a service called Patent Integration, which is an integrated patent search and patent analysis service. With reasonable pricing and a simple user interface such that even beginners can quickly search for and analyze patent information by company or technology from a web browser, please consider using it for detailed patent searches, patent analysis, and IP landscaping.
Patent Integration has a patent-landscaping function that can visually represent a set of tens of thousands of patents/patent applications. This allows you to convincingly show the technical positions of your company and its competitors to your management and business strategists in order to formulate management strategies and business strategies.
The changes in the number of patent filings of 症状 over the last 20 years (JP) are shown below.
The change in the number of patents/patent applications is the most basic index in patent analysis. By examining the change in the number of patents/patent applications, you can see the status of technological development and R&D focus for each company or technology. It should be noted that since there is a one and a half year lag between the filing and the laying open of patent applications, it is not possible to analyze the situation more recently than one and half years prior to the present.
In this report, you can only see the change in the number of patents/patent applications by company or technology, whereas Patent Integration allows you to quickly compare the number of patent applications with your competitors in each technical field by cross-referencing with other keywords and patent classifications.
This patent analysis report was created for a patent search set of 24,308 cases retrieved by applying the following search formula and analysis period to the following patent database. Patent information such as a patent analysis result, a patent map, and a patent landscape can be freely used for patent searches, analysis, and work on intellectual property strategies, including IP landscaping.
The number of patents and changes in the number of patents of other companies (competitors) in the same industry as 症状 are shown below.
Comparison of changes in the number of patents with peers and competitors is an important analytical index for understanding the intellectual property strategies of each company. By checking the transition of the number of patents for each company / competitor, you can check the status of focus on technology development and R&D for each company / technology.
It should be noted that patents have a time lag of one and a half years from filing to publication, so it is not possible to analyze the situation more recent than one and a half years.
If you want to find out more information, " Patent Integration , You can compare the number of patent applications with competitors in each technical field in a short time by multiplying with other keywords and patent classifications.Please use it for more detailed patent information analysis such as selection of M&A candidate destinations and alliance destinations.
Comparing the number of applications of each company, エフホフマン-ラロシュアーゲー has the highest number of joint applications in the last in the last 3 years (2022 to 2024) with 19 cases, followed by ヤンセンファーマシューティカエヌベー with 19 cases.
Name | Cases |
---|---|
エフホフマン-ラロシュアーゲー | 19 cases |
ヤンセンファーマシューティカエヌベー | 19 cases |
ノバルティスアーゲー | 13 cases |
ザリージェンツオブザユニバーシティオブカリフォルニア | 13 cases |
ジェネンテックインコーポレイテッド | 11 cases |
ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング | 7 cases |
武田薬品工業株式会社 | 3 cases |
ブリストル-マイヤーズスクイブカンパニー | 3 cases |
Comparing the number of applications of each company, ノバルティスアーゲー has the highest number of joint applications in the last for the target period (2014 to 2024) with 379 cases, followed by エフホフマン-ラロシュアーゲー with 232 cases.
Name | Cases |
---|---|
ノバルティスアーゲー | 379 cases |
エフホフマン-ラロシュアーゲー | 232 cases |
ザリージェンツオブザユニバーシティオブカリフォルニア | 174 cases |
ジェネンテックインコーポレイテッド | 169 cases |
ヤンセンファーマシューティカエヌベー | 150 cases |
ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング | 132 cases |
ブリストル-マイヤーズスクイブカンパニー | 130 cases |
武田薬品工業株式会社 | 122 cases |
メルク・シャープ・アンド・ドーム・コーポレーション | 39 cases |
グラクソグループリミテッド | 4 cases |
Below is a patent map showing changes in the number of applications for JP patents of 11 companies in the same industry over the past 20 years.
The number of patents and changes in the number of patents of other companies (competitors) in the same industry as 症状 are shown below.
Comparison of changes in the number of patents with peers and competitors is an important analytical index for understanding the intellectual property strategies of each company. By checking the transition of the number of patents for each company / competitor, you can check the status of focus on technology development and R&D for each company / technology.
It should be noted that patents have a time lag of one and a half years from filing to publication, so it is not possible to analyze the situation more recent than one and a half years.
If you want to find out more information, " Patent Integration , You can compare the number of patent applications with competitors in each technical field in a short time by multiplying with other keywords and patent classifications.Please use it for more detailed patent information analysis such as selection of M&A candidate destinations and alliance destinations.
Among the top coapplicants, エフホフマン-ラロシュアーゲー has the highest number of joint applications in the last in the last 3 years (2022 to 2024) with 19 cases, followed by ヤンセンファーマシューティカエヌベー with 19 cases.
Name | Cases |
---|---|
エフホフマン-ラロシュアーゲー | 19 cases |
ヤンセンファーマシューティカエヌベー | 19 cases |
ノバルティスアーゲー | 13 cases |
ザリージェンツオブザユニバーシティオブカリフォルニア | 13 cases |
ジェネンテックインコーポレイテッド | 11 cases |
ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング | 7 cases |
武田薬品工業株式会社 | 3 cases |
Among the top coapplicants, ノバルティスアーゲー has the highest number of joint applications in the last for the target period (2014 to 2024) with 379 cases, followed by エフホフマン-ラロシュアーゲー with 232 cases.
Name | Cases |
---|---|
ノバルティスアーゲー | 379 cases |
エフホフマン-ラロシュアーゲー | 232 cases |
ザリージェンツオブザユニバーシティオブカリフォルニア | 174 cases |
ジェネンテックインコーポレイテッド | 169 cases |
ヤンセンファーマシューティカエヌベー | 150 cases |
ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング | 132 cases |
武田薬品工業株式会社 | 122 cases |
Below is a ranking of the number of JP patent applications by 症状’s top 7 coapplicants over the last 20 years.
Below is a patent map showing the changes in the numbers of JP patent filings by 症状’s top 7 coapplicants over the last 20 years.
症状 filed 379 joint applications with ノバルティスアーゲー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 158 cases in total) is 26.3, and the median is 25.5. The coefficient of variation (standard deviation/mean) is 0.7, and there have been relatively large fluctuations in the number of filings from year to year.
The highest number of filings in 2016 with 59 cases, and their lowest number in 2022 with 13 cases.
Index | Value |
---|---|
Average | 26.3 patents |
Std Dev | 17.3 |
COV | 0.7 |
Year | Cases | YOY |
---|---|---|
2022 year | 13 cases | -45.8 % |
2021 year | 24 cases | -11.11 % |
2020 year | 27 cases | -34.1 % |
症状 filed 232 joint applications with エフホフマン-ラロシュアーゲー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 119 cases in total) is 19.8, and the median is 19.0. The coefficient of variation (standard deviation/mean) is 0.5, and there have been big fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2021 with 34 cases, and their lowest number in 2022 with 19 cases.
Index | Value |
---|---|
Average | 19.8 patents |
Std Dev | 10.5 |
COV | 0.5 |
Year | Cases | YOY |
---|---|---|
2022 year | 19 cases | -44.1 % |
2021 year | 34 cases | +21.43 % |
2020 year | 28 cases | +47.4 % |
症状 filed 132 joint applications with ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 60 cases in total) is 10.0, and the median is 10.5. The coefficient of variation (standard deviation/mean) is 0.6, and there have been relatively large fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2014 with 26 cases, and their lowest number in 2022 with 7 cases.
Index | Value |
---|---|
Average | 10.0 patents |
Std Dev | 6.0 |
COV | 0.6 |
Year | Cases | YOY |
---|---|---|
2022 year | 7 cases | -41.7 % |
2021 year | 12 cases | +33.3 % |
2020 year | 9 cases | -55.0 % |
症状 filed 169 joint applications with ジェネンテックインコーポレイテッド for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 72 cases in total) is 12.0, and the median is 13.5. The coefficient of variation (standard deviation/mean) is 0.5, and there have been big fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2016 with 31 cases, and their lowest number in 2022 with 11 cases.
Index | Value |
---|---|
Average | 12.0 patents |
Std Dev | 5.9 |
COV | 0.5 |
Year | Cases | YOY |
---|---|---|
2022 year | 11 cases | -35.3 % |
2021 year | 17 cases | +54.5 % |
2020 year | 11 cases | -35.3 % |
症状 filed 150 joint applications with ヤンセンファーマシューティカエヌベー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 82 cases in total) is 13.7, and the median is 17.0. The coefficient of variation (standard deviation/mean) is 0.5, and there have been big fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2017 with 29 cases, and their lowest number in 2016 with 5 cases.
Index | Value |
---|---|
Average | 13.7 patents |
Std Dev | 7.2 |
COV | 0.5 |
Year | Cases | YOY |
---|---|---|
2022 year | 19 cases | -5.00 % |
2021 year | 20 cases | +33.3 % |
2020 year | 15 cases | -21.05 % |
The following shows JP patents held by 症状 that have had an invalidation trial against them demanded or an opposition filed against them by a third party, and 症状’s JP patents/patent applications of high importance cited by Examiners in patent examination processes.
By noting the most important patents, you can obtain knowledge of the competitive business environment in which 症状 is placed (e.g., whether it is a fiercely competitive environment or an oligopolistic market and the like). In general, it can be understood that a company with a large number of demands for invalidation trials is developing their business in a business environment where IP disputes are common.
If you want to search for more detailed information, you can use Patent Integration to retrieve and download by company cited patents/patent applications or patents undergoing invalidation trials. You can quickly extract important patents from a patent set that includes multiple competitors by cross-referencing with other keywords and patent classifications. Please consider using it for searches for important patents/patent applications.
In the last 3 years (2021-11-01 ~ 2024-10-31), there were 7 patents Invalidation Trial from third parties. The average number of Invalidation Trial is 1.1 times. The most recently Invalidation Trial patent is 特許6995822 "DPP IVインヒビターの使用" (Invalidation Trial day 2024-06-25) , next is 特許4786866 "クロライドチャンネルオープナーとしてのプロスタグランジンアナログ" (Invalidation Trial day 2024-04-03) .
- | No. | Title | Invalidation Trial days |
---|---|---|---|
1 | 特許6995822 | DPP IVインヒビターの使用 | 2024-06-25 |
2 | 特許4786866 | クロライドチャンネルオープナーとしてのプロスタグランジンアナログ | 2024-04-03 |
3 | 特許6556767 | DPP−4阻害剤(リナグリプチン)を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬 | 2024-03-19 |
4 | 特許7185426 | S1P受容体モジュレーターの投与計画 | 2023-07-10 |
5 | 特許5734564 | DPP IVインヒビターの使用 | 2023-07-10 |
6 | 特許5474043 | (+)−2−[1−(3−エトキシ−4−メトキシフェニル)−2−メチルスルホニルエチル]−4−アセチルアミノイソインドリン−1,3−ジオンを含む固形物形態、その組成物およびその使用 | 2023-05-31 |
7 | 特許5813293 | DPP IVインヒビターの使用 | 2023-03-07 |
Of the patent applications filed in the last 10 years (2014-11-01 to 2024-10-31), 6 patents/patent applications were invalidation trial more than once in the examination process of other patent applications. The mean of the number of invalidation trial is 1.2. The most invalidation trial patent is 特許5906333 "プロタンパク質コンベルターゼスブチリシンケクシン9型(PCSK9)に対する抗原結合タンパク質" (2 times) , and the next most invalidation trial patent is 特許6522072 "イズロン酸−2−スルファターゼのCNS送達のための方法および組成物" (1 times) .
- | No. | Title | |
---|---|---|---|
1 | 特許5906333 | プロタンパク質コンベルターゼスブチリシンケクシン9型(PCSK9)に対する抗原結合タンパク質 | 2 times |
2 | 特許6522072 | イズロン酸−2−スルファターゼのCNS送達のための方法および組成物 | 1 times |
3 | 特許6466538 | 治療薬のCNS送達 | 1 times |
4 | 特許6074462 | 抗−TNFα抗体の投与方法 | 1 times |
5 | 特許6302529 | 抗−TNFα抗体の投与方法 | 1 times |
In the last 3 years (2021-11-01 ~ 2024-10-31), there were 17 patents Opposition from third parties. The average number of Opposition is 1.0 times. The most recently Opposition patent is 特許7448953 "眼疾患のための細胞モデル及び治療関連出願への相互参照" (Opposition day 2024-04-17) , next is 特許7282155 "頭皮用外用組成物" (Opposition day 2023-11-24) .
- | No. | Title | Opposition days |
---|---|---|---|
1 | 特許7448953 | 眼疾患のための細胞モデル及び治療関連出願への相互参照 | 2024-04-17 |
2 | 特許7282155 | 頭皮用外用組成物 | 2023-11-24 |
3 | 特許7244922 | 化学修飾された一本鎖RNA編集オリゴヌクレオチド | 2023-09-20 |
4 | 特許7237544 | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 | 2023-09-11 |
5 | 特許7223103 | 錐体外路症状診断装置及び錐体外路症状診断プログラム | 2023-08-14 |
6 | 特許7210036 | アルツハイマー病および他の神経変性障害のためのバイオマーカーおよび診断方法 | 2023-07-20 |
7 | 特許7182765 | 月経に伴う身体的及び/又は精神的不快症状の改善システム | 2023-06-02 |
8 | 特許7181540 | 月経に伴う身体的及び/又は精神的不快症状の改善システム | 2023-06-01 |
9 | 特許7074345 | 一本鎖RNA編集オリゴヌクレオチド | 2022-11-18 |
10 | 特許7008337 | ヒト機能性角膜内皮細胞およびその応用 | 2022-08-09 |
In the last 3 years (2021-11-01 ~ 2024-10-31), there were 56 patents Protest from third parties. The average number of Protest is 1.7 times. The most recently Protest patent is 特表2024-504870 "含窒素架橋複素環化合物、その調製方法及びその医薬的応用" (Protest day 2024-09-02) , next is 特表2023-505246 "無機物および/またはビタミンならびに多糖を含む製剤、その組成物ならびに前記無機物および/またはビタミンの補充におけるその使用" (Protest day 2024-08-22) .
- | No. | Title | Protest days |
---|---|---|---|
1 | 特表2024-504870 | 含窒素架橋複素環化合物、その調製方法及びその医薬的応用 | 2024-09-02 |
2 | 特表2023-505246 | 無機物および/またはビタミンならびに多糖を含む製剤、その組成物ならびに前記無機物および/またはビタミンの補充におけるその使用 | 2024-08-22 |
3 | 特開2023-168547 | 眼科組成物 | 2024-06-26 |
4 | 特表2022-506635 | オリゴ糖組成物およびその使用方法 | 2024-06-03 |
5 | 特開2022-017829 | ミトコンドリア機能活性化剤 | 2024-05-15 |
6 | 特許7564637 | 情報処理システム、情報処理方法、及び制御プログラム | 2024-05-15 |
7 | 特許7513305 | 3次元培養された幹細胞から細胞外小胞体を製造する方法 | 2024-05-02 |
8 | 特開2022-028813 | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 | 2024-05-02 |
9 | 特開2023-022363 | 細胞保護用剤 | 2024-04-18 |
10 | 特開2022-149767 | 表皮の保湿因子又はバリア機能因子の発現増強剤 | 2024-04-15 |
11 | 特許7487872 | 医療システム及びそれを実行する方法 | 2024-04-03 |
12 | 特表2023-546415 | ペットフード組成物 | 2024-03-13 |
13 | 特許7038388 | 医療システム及びそれを実行する方法 | 2024-03-10 |
14 | 特表2023-525856 | ATI消化のための方法及び組成物 | 2024-02-28 |
15 | 特開2023-175853 | 疾患診断および健康評価のための個々の対象の低分子生化学プロファイリングの方法 | 2024-02-16 |
16 | 特許7554475 | 健康支援装置、健康支援システム、健康支援方法 | 2024-02-15 |
17 | 特表2023-534047 | オリゴ糖組成物及び使用方法 | 2024-02-07 |
18 | 特許7542530 | 緩衝塩及びアミノ酸を含有する粉末、そのような粉末の栄養製品への再構成、並びにそのような栄養製品を使用する方法 | 2024-01-30 |
19 | 特許7455021 | マッサージシステム | 2023-12-27 |
20 | 特開2023-161047 | 育毛促進用組成物 | 2023-12-20 |
Of the patent applications filed in the last 10 years (2014-11-01 to 2024-10-31), 105 patents/patent applications were protest more than once in the examination process of other patent applications. The mean of the number of protest is 1.6. The most protest patent is 特開2019-022520 "組成物" (9 times) , and the next most protest patent is 特許6969717 "組成物" (5 times) .
- | No. | Title | |
---|---|---|---|
1 | 特開2019-022520 | 組成物 | 9 times |
2 | 特許6969717 | 組成物 | 5 times |
3 | 特開2021-116296 | コロナウイルス感染の治療におけるファビピラビルの使用 | 4 times |
4 | 特許6734475 | 画像処理装置及びプログラム | 4 times |
5 | 特許7058599 | 中鎖トリグリセリド組成物 | 4 times |
In the last 3 years (2021-11-01 ~ 2024-10-31), there were 374 patents Inspection from third parties. The average number of Inspection is 1.5 times. The most recently Inspection patent is 特許7565921 "急性骨髄性白血病の治療のための、CD70及びベネトクラクス、BCL-2阻害剤、組合せ療法" (Inspection day 2024-09-20) , next is 特表2021-502097 "標的化CRISPR送達プラットフォーム" (Inspection day 2024-09-17) .
- | No. | Title | Inspection days |
---|---|---|---|
1 | 特許7565921 | 急性骨髄性白血病の治療のための、CD70及びベネトクラクス、BCL-2阻害剤、組合せ療法 | 2024-09-20 |
2 | 特表2021-502097 | 標的化CRISPR送達プラットフォーム | 2024-09-17 |
3 | 特表2024-504870 | 含窒素架橋複素環化合物、その調製方法及びその医薬的応用 | 2024-09-12 |
4 | 特表2022-538009 | コハク酸プロドラッグ、コハク酸プロドラッグを含有する組成物、及びその使用 | 2024-09-06 |
5 | 特許7555346 | 疾患の治療のためのロイシン、アセチルロイシン、及び関連類似体 | 2024-08-30 |
6 | 特表2023-518552 | LNP023の結晶形態 | 2024-08-27 |
7 | 特許6511617 | 皮膚内の血管の治療装置 | 2024-08-15 |
8 | 特表2024-521164 | 感染後自己免疫性糖尿病を治療するための方法 | 2024-08-14 |
9 | 特表2023-548848 | ループスを処置するための方法および組成物 | 2024-08-14 |
10 | 特開2021-191785 | 治療活性化合物の医薬組成物 | 2024-07-25 |
11 | 特許7524196 | 動的閾値を使用して局所用組成物を選択的に適用するためのデバイス及び方法 | 2024-07-24 |
12 | 特開2023-168547 | 眼科組成物 | 2024-07-23 |
13 | 特表2022-546246 | 軟組織のレーザベースの治療のためのシステム | 2024-07-23 |
14 | 特開2022-084946 | 様々な疾患および障害の治療のためにMASP-1および/またはMASP-2および/またはMASP-3を阻害する組成物および方法 | 2024-07-11 |
15 | 特開2022-069555 | オキシステロールおよびその使用方法 | 2024-07-03 |
16 | 特許7007770 | 眼症状改善剤および眼症状の改善方法 | 2024-07-02 |
17 | 特開2024-000504 | HMGB1の発現制御剤;急性肺損傷、急性呼吸窮迫症候群または敗血症の予防薬または治療薬、あるいはそれらの改善方法 | 2024-07-02 |
18 | 特開2022-110130 | 新規の阻害剤 | 2024-06-27 |
19 | 特許7554475 | 健康支援装置、健康支援システム、健康支援方法 | 2024-06-26 |
20 | 特表2020-535232 | 透過エンハンサーを含む送達医薬組成物 | 2024-06-25 |
Of the patent applications filed in the last 10 years (2014-11-01 to 2024-10-31), 700 patents/patent applications were inspection more than once in the examination process of other patent applications. The mean of the number of inspection is 1.3. The most inspection patent is 特開2017-149726 "B細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療" (46 times) , and the next most inspection patent is 特開2020-045332 "慢性便秘症を治療するための医薬組成物" (11 times) .
- | No. | Title | |
---|---|---|---|
1 | 特開2017-149726 | B細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療 | 46 times |
2 | 特開2020-045332 | 慢性便秘症を治療するための医薬組成物 | 11 times |
3 | 特開2018-131469 | 磁気双極子安定化溶液の使用を含む疾患を処置または改善する方法および行動を向上させる方法 | 9 times |
4 | 特開2017-002035 | ソフトコンタクトレンズが装用されたドライアイ患者の眼に点眼されるように用いられることを特徴とするドライアイ治療剤 | 8 times |
5 | 特開2021-116296 | コロナウイルス感染の治療におけるファビピラビルの使用 | 8 times |
Of the patent applications filed in the last 10 years (2014-11-01 to 2024-10-31), 3,442 patents/patent applications were cited more than once in the examination process of other patent applications. The mean of the number of cited is 2.3. The most cited patent is 特許6594413 "携帯デバイスを介する非侵襲的神経刺激" (63 times) , and the next most cited patent is 特表2018-501927 "片頭痛の頭痛の防止的処置のための方法およびシステム" (42 times) .
- | No. | Title | |
---|---|---|---|
1 | 特許6594413 | 携帯デバイスを介する非侵襲的神経刺激 | 63 times |
2 | 特表2018-501927 | 片頭痛の頭痛の防止的処置のための方法およびシステム | 42 times |
3 | 特許6140331 | 主軸または主軸を駆動するモータの故障予知を学習する機械学習装置および機械学習方法、並びに、機械学習装置を備えた故障予知装置および故障予知システム | 42 times |
4 | 特許6778114 | イミド系タンパク質分解モジュレーター及び関連する使用方法 | 32 times |
5 | 特許6871379 | 治療及び/又は運動の指導プロセス管理システム、治療及び/又は運動の指導プロセス管理のためのプログラム、コンピュータ装置、並びに方法 | 30 times |
"Patent Integration Report" is a web service provided by "Patent Integration Co., Ltd." operated by patent attorneys who are experts in intellectual property rights. Based on the latest patent data, this is one of the largest patent report services in Japan that provides information on technology trends in various companies and technology fields.
The purpose of this web service is to make intellectual property information familiar to many people, regardless of whether they have an interest in intellectual property rights, and to make use of it.
We actively provide various types of patent information that can be used in various media articles such as newspapers, magazines, and web media. Please feel free to contact us from "Inquiry form for details on the content of patent information that can be provided, conditions for provision, etc. Please contact us.
All rights related to the data, documents and charts belong to "an integrated patent search/analysis service provider, Patent Integration". Please specify the source “Patent Integration Report, URL: https://patent-i.com/report/en/" when inserting them into in-house materials, external report materials, etc., regardless of whether they are paid or free of charge.
Patent data is obtained by aggregating and analyzing the latest patent data issued by the Patent Offices of respective countries and jurisdictions and by WIPO. Although we take great care in publishing and analyzing the results, we do not guarantee the correctness of the data. We appreciate your understanding.
If you have any concerns about this service, please feel free to contact us.
All rights to the data, documents, figures and tables are reserved by e-Patent. When publishing internal documents, external reports, etc. (whether paid or free of charge), please use the following URL: https://e-patent.co.jp/.
e-Patent will not be liable for any damages or losses arising from the use of the global patent application status, ranking information, or population search formula in the "SDGs Global Company Ranking from a Patent Perspective". Items with ● in front of the target are not supported at this time (judged to be difficult to approach from the patent information analysis).
There is no problem to cite patent application status and ranking information, but please clearly indicate "Source: e-Patent Co.
Credit notation
・MeCab user dictionary for science technology term © National Bioscience Database Center licensed under CC Attribution-Share Alike 4.0 International